Pancreatic enzymes for healthy digestion
- Plant and animal sourced enzymes to improve and enhance digestion
- Improves nutrient absorption
- Helps reduce inflammation
$42.25 — or subscribe and save 20%
Enzymes are as essential to life as food and water, yet they remains one of the most underappreciated factors in the field of clinical nutrition. They are the catalysts that facilitate the breakdown of food into nutrients and other particles that are absorbed by, and excreted from, our bodies. Those who wish to support their digestive system, improve overall gut health and energy, boost immunity and alleviate uncomfortable digestive symptoms such as gas and bloating can benefit from enzyme supplementation.
AOR Zymes contains proteases to digest proteins, alpha amylase to digest starches, lipase to digest fats and alpha galactosidase for hard-to-digest polysaccharides found in legumes and vegetables that can cause gas and bloating. They are porcine pancreatic enzymes, meaning they are derived from pigs. Pancreatic enzymes from a mammalian source tend to be more effective than plant-based enzymes since they are similar to the enzymes naturally present in the human body.
Enzyme supplementation promotes the health of the digestive organs by facilitating digestion itself. It increases the efficiency of the digestive process by alleviating some of the burden from the digestive organs and improving nutrient absorption. Since the body cannot access nutrients in undigested food, the more food particles can be broken down, the more nutrients are made accessible to the body for absorption. In addition, poor breakdown of food particles is thought to contribute to allergies and various digestive diseases.
AOR Zymes provides well-rounded digestive support and improves overall health and energy. AOR Zymes utilizes porcine pancreatic enzymes because their composition is similar to human digestive enzymes.
AOR Zymes is formulated with porcine derived pancreatic enzymes because they are similar to human pancreatic enzymes. AOR Zymes helps reduce gas and bloating following a meal rich in fermentable carbohydrates such as vegetables, legumes and whole grains.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, corn, soy, nuts, eggs, fish or shellfish.
Take one capsule immediately before a meal one to four times daily, or as directed by a qualified health care practitioner. Use the smallest effective dose which controls symptoms. Swallow whole; do not open capsules.
Consult a health care practitioner for prolonged use or for use beyond 4 weeks. Consult a health care practitioner prior to use if you are pregnant, breastfeeding, if you have diabetes, pancreatitis, pancreatic exocrine insufficiency or cystic fibrosis. Do not use if you are sensitive to pancreatic enzymes or pork proteins. Nausea, vomiting, abdominal pain/epigastric pain, heartburn, and/or hypersensitivity/allergy have been known to occur, in which case discontinue use and consult a health care practitioner. If symptoms persist or worsen, discontinue use and consult a health care practitioner.
- Gastrointestinal health
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: silicon dioxide, maltodextrin, sodium stearyl fumarate. Capsule: hypromellose.
The role of digestion in overall health and wellness cannot be overstated. The importance of healthy digestion in metabolic and cardiovascular health has been established. The aim of this double-blind, randomized study was to evaluate the effect of supplementation with whey protein, containing proteases on markers of general physical health, metabolic function, hepato-renal function, and cardiovascular health in active, healthy men.
Participants were randomized to receive either whey protein, containing fundal protease enzyme or just whey protein for 30 days. Improvement in digestion, total cholesterol, low-density lipoprotein (LDL) cholesterol, and serum calcium levels.
This double-blind, placebo-controlled, crossover clinical study was carried out to determine whether supplementation with microencapsulated pancreatic enzymes have an effect on postprandial symptoms, after the ingestion of a high calorie, high-fat meal. Following the ingestion of the meal and either a placebo or pancreatic enzymes, the severity of gastrointestinal symptoms and flatus passafes were recorders for up to 17 hours. In addition, end-alveolar samples were obtained hourly for 10 hours.
The results show a reduction in bloating over the entire recording period, with significant reductions in bloating, gas, and fullness during the dinner to bedtime period in the supplementation group, compared to the placebo group. These effects led the researchers to conclude that pancreatic enzyme supplementation might be beneficial in patients with irritable bowel syndrome (IBS).
The first line of therapy for many patients with fat malabsorption, with exocrine pancreatic insufficiency, includes pancreatic enzyme supplementation, even prior to sufficient clinical evidence for its use. The aim of this systematic review and meta-analysis, published in 2009, aimed to determine if pancreatic enzyme supplementation is superior to placebo or other supplementation for treating fat malabsorption. 12 randomized, cross-over, controlled studies were included in this analysis, with data showing that pancreatic enzymes were superior to placebo for fat absorption. The authors conclude that pancreatic enzyme supplementation, not specific to any branded product or specific delivery system, improve symptoms of fat malabsorption in patients with exocrine pancreatic insufficiency.
This aim of this double-blind, placebo-controlled, crossover design clinical study was to evaluate the effect of acid-resistant lipase supplementation on upper gastrointestinal symptoms, including fullness and bloating, as well as on gastric myoelectrical activity after healthy subjects ingested a high-fat, liquid meal. Participants were randomized to receive either a placebo or lipase in an acid-resistant capsule (280 mg) immediately before a fatty meal and rated their stomach fullness, bloating, and nausea before and at times intervals for an hour following their meal.
The results showed that stomach fullness, bloating, and nausea increased significantly 10 minutes after the ingestion of the fatty meal. With the administration of lipase, there were significant decreases in reports of stomach fullness.
The objective of this randomized, controlled clinical study was to evaluate the effect of administration of a combination of inositol, beta-glucans, and digestive enzymes in improving gastrointestinal symptoms in patients affected by inflammatory bowel syndrome (IBS). Patients were randomized to one of two groups – group 1 received supplementation, while the second group did not receive any therapy.
The results showed that supplementation led to an improvement in bloating, flatulence, and abdominal pain, with a slight increase of urgency for bowel movements, showing that digestive enzymes can help improve symptoms of IBS, by reducing the presence of gas inside the intestinal lumen.
A similar intention to treat, double-blind, randomized, crossover study evaluating the effect of a lipase supplement, compared to a placebo, in reducing postprandial IBS-related diarrhea. The results show an improvement in all symptoms, especially a significant improvement in cramping, bloating, borborygmi (the rumbling sounds made by the movement of fluid/gas in the intestines), the urge to defecate, global pain and increase in stool firmness. These study results show the benefit of digestive enzymes in reducing the inflammation, as well as other symptoms of IBS.
Deficiency Related Disorders:
Fabry disease is a lysosomal storage disorder resulting from a deficiency in alpha-galactosidase A activity and globotriaosylceramide accumulation causing renal insufficiency, strokes, hypertrophic cardiomyopathy, and early death. The aim of this study was to assess the clinical effect of α-galactosidase A supplementation in the progression of disease symptoms in patients with Fabry disease. Following supplementation, participants were assessed for severe clinical events, renal function, and cardiac structure.
This 10-year study documents the effectiveness of agalsidase beta (1 mg/kg/2 weeks) in patients with Fabry disease. Most patients remained alive and event-free. Patients who initiated treatment at a younger age and with less kidney involvement benefited the most from therapy. Patients who initiated treatment at older ages and/or had advanced renal disease experienced disease progression.
The aim of this 2:1 multicenter, randomized, placebo-controlled, double-blind clinical study was to evaluate the effect of alpha-galactosidase supplementation on the onset of a composite clinical outcome of renal, cardiovascular, cerebrovascular events and death in patients with advanced Fabry disease. Patients received either a placebo or intravenous infusions of alpha-galactosidase beta every 2 weeks for up to 35 months, with a median time of 18.5 months.
The results showed that supplementation with alpha-galactosidase slowed progression to the composite clinical outcome of renal, cardiac, and cerebrovascular complications and death compared with placebo in patients with advanced Fabry disease. Therapeutic intervention before irreversible organ damage may provide greater clinical benefit.
Patients with cystic fibrosis usually need to supplement their diet with lipase because they cannot digest fat properly. Pancreatic enzyme replacement therapy leads to normalized lipase function in 40% of the patients. Porcine lipase has been the treatment of choice for steatorrhea due to pancreatic exocrine deficiency for several decades. The aim of this phase III 12-month open-label trial was to assess the safety, tolerability, and long-term nutritional effects of liprotamase in patients with cystic fibrosis and exocrine pancreatic insufficiency in patients aged 7 or older.
The results show that supplementation with liprotamase was well tolerated and led to associated age appropriate growth and weight gain or maintenance in CF patients.
The effect of protease supplementation in reducing inflammation and eccentric exercise-induced skeletal muscle damage and inflammation was evaluated in this randomized, placebo-controlled, double-blinded clinical study. The objective of this study is based on the hypothesis that protease supplementation can reduce the damaging effects of exercise and accelerate the recovery of muscle function by regulating inflammation. Participants were randomized to receive either 5.83 g of cellulose placebo or proteolytic supplement, containing fungal proteases, bromelain, and papain. After the supplementation period, subjects donated blood samples before performing a 45-min downhill treadmill protocol at 60% of VO2max. An additional four blood draws and three muscle function tests were performed during the next 48 hours.
Significant differences were observed between the placebo and supplementation group, with improvements observed in the protease supplemented group in terms of muscle strength losses, leukocyte markers, and inflammatory markers.
Other studies are listed under gastrointestinal health.